12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Aspen, GlaxoSmithKline sales and marketing update

GlaxoSmithKline will divest 25 non-promoted and generic products in Australia to Aspen's Aspen Global Inc. subsidiary for about £172 million ($270.2 million) in cash. Products include antiviral drug ...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >